Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

IMPORTANCE: Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-type (WT) MCRC may be valuable for these patients. OBJECTIVE: To compare the anti-EGFR monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Napolitano, Stefania, De Falco, Vincenzo, Martini, Giulia, Ciardiello, Davide, Martinelli, Erika, Della Corte, Carminia Maria, Esposito, Lucia, Famiglietti, Vincenzo, Di Liello, Alessandra, Avallone, Antonio, Cardone, Claudia, De Stefano, Alfonso, Montesarchio, Vincenzo, Zampino, Maria Giulia, Bordonaro, Roberto, Scartozzi, Mario, Santini, Daniele, Di Maio, Massimo, De Vita, Ferdinando, Altucci, Lucia, Marrone, Francesca, Ciardiello, Fortunato, Troiani, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196928/
https://www.ncbi.nlm.nih.gov/pubmed/37200022
http://dx.doi.org/10.1001/jamaoncol.2023.0655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196928/
https://www.ncbi.nlm.nih.gov/pubmed/37200022
http://dx.doi.org/10.1001/jamaoncol.2023.0655

Ejemplares similares